Loading...

PE Streptavidin

Pricing & Availability
Regulatory Status
RUO
Other Names
Streptavidin-Phycoerythrin, SAv-PE
Ave. Rating
Submit a Review
Product Citations
publications
SAV_PE_082808.jpg
C57BL/6 splenocytes stained with 145-2C11 biotin, followed by SAV-PE
  • SAV_PE_082808.jpg
    C57BL/6 splenocytes stained with 145-2C11 biotin, followed by SAV-PE
See PE spectral data
Cat # Size Price Quantity Check Availability Save
405203 100 µg 56 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
405204 500 µg 195 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Streptavidin binds to biotin with high affinity. Streptavidin-Phycoerythrin (PE) is useful for detecting biotinylated antibodies. The excitation of PE by 488 nm laser light induces a light emission maximum of 575 nm.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Mouse, Rat, All Species
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
Streptavidin is conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml (concentration relates to the Streptavidin only component of the conjugate)
Storage & Handling
The streptavidin-PE solution should be stored undiluted between 2°C and 8°C, and protected from exposure to light. Do not freeze.
Application

FC - Quality tested

ICFC - Verified
Recommended Usage

This streptavidin product is quality control tested by immunofluorescent staining with flow cytometric analysis. The concentration provided is based upon molecular mass of streptavidin independent of any additional molecular mass that might be added by the PE conjugation. For flow cytometric staining, the suggested use of this reagent is ≤0.06 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Streptavidin-Phycoerythrin (PE) is useful as a second step reagent for indirect immunofluorescent staining, when used in conjunction with biotinylated primary antibodies. The average molecular weight of Streptavidin-PE is 360 kD and Streptavidin alone is 52 kD.

Application References

(PubMed link indicates BioLegend citation)
  1. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245.
  2. Nishimoto KP,et al. 2008. J. Immunol. 181:4010.PubMed
  3. Niki T, et al. 2009. J. Biol. Chem. 284:32344. PubMed
  4. Shibui A, et al. 2011. Exp Parasitol. 129:318. PubMed
  5. Scatizzi JC, et al. 2012. J. Immunol. 188:3307. PubMed
  6. Yamakawa N, et al. 2012. Int Immunol. 25:45. PubMed
  7. Shibata T, et al. 2012. Int Immunol. 24:613. PubMed
  8. Baccala R, et al. 2012. J. Immunol. 189:5976. PubMed
  9. Grevers LC, et al. 2013. Ann Reheum Dis. 72:278. PubMed
  10. Woo SJ, et al. 2013. J Leukoc Biol. 93:363. PubMed
  11. Ashbaugh JJ, et al. 2013. J. Immunol. 190:4525. PubMed
  12. Reading JL, 2013. J. immunol. 190:4542. Pubmed.
  13. Kanno A, et al. 2013. Int Immunol. 25:413. PubMed
  14. Gunaydin G, et al. 2014. Vaccine. 32:470. PubMed
  15. Lyngaa R, et al. 2014. Clin Cancer Res. 20:1768. PubMed
  16. Datta S, et al. 2014. J Leukoc Biol. 95:853. PubMed
  17. He X, et al. 2014. J Immunol. 193:1314. PubMed
  18. Wang W, et al. 2014. PNAS. 111:14466. PubMed
  19. Murakami Y, et al. 2014. J Immunol. 193:5208. PubMed
  20. Lucas A, et al. 2015. PLoS One. 10:117160. PubMed
  21. Kim Yu, et al. 2015. PLoS One. 10:120294. PubMed
  22. Hua X, et al. 2015. PloS One. 10:128039. PubMed
Product Citations
  1. Eger C, et al. 2016. PLoS One. 11: 0150479. PubMed
  2. Yang J, et al. 2016. Sci Rep. 6:38238. PubMed
  3. Chen T, et al. 2016. J Exp Med. 13(13):3025-3039. PubMed
  4. Wang H, et al. 2020. Mol Oncol. 14:991. PubMed
  5. Zhang Y, et al. 2017. Journal of Immunological Methods. 10.1016/j.taap.2017.05.020. PubMed
  6. Wu Y, et al. 2021. Immunity. 54:2595. PubMed
  7. Goel RR, et al. 2022. Cell. 185:1875. PubMed
  8. Campisi L, et al. 2022. Nature. 606:945. PubMed
  9. Grégoire C, et al. 2022. Immunity. 55:1216. PubMed
  10. Wu Y, et al. 2022. Sci Adv. 8:eabm7833. PubMed
  11. Cao Y, et al. 2023. Nature. 614:521. PubMed
  12. Weskamm LM, et al. 2022. STAR Protoc. 3:101902. PubMed
  13. Mekkaoui L, et al. 2023. Mol Ther Methods Clin Dev. 28:116. PubMed
  14. Lombard-Vadnais F, et al. 2023. iScience. 26:105852. PubMed
  15. Hernandez SPA, et al. 2023. Front Immunol. 13:1035344. PubMed
  16. Pušnik J, et al. 2023. Nat Commun. 14:572. PubMed
  17. Knyphausen P, et al. 2023. Nat Commun. 14:768. PubMed
  18. Yeh CH, et al. 2022. Immunity. 55:272. PubMed
  19. Feng J, et al. 2022. Immunity. 55:405. PubMed
  20. Tas JMJ, et al. 2022. Immunity. 55:1856. PubMed
  21. Melzi E, et al. 2022. Immunity. 55:2168. PubMed
  22. Vyasamneni R, et al. 2023. Cell Rep Methods. 3:100388. PubMed
  23. Ke F, et al. 2023. Elife. 12:. PubMed
  24. Li D, et al. 2023. Int J Oncol. 62:. PubMed
  25. Silva RP, et al. 2023. Elife. 12:. PubMed
  26. Nozuma S, et al. 2023. JCI Insight. 8:. PubMed
  27. García-Vega M, et al. 2023. iScience. 26:106562. PubMed
  28. Liu Y, et al. 2023. Nat Commun. 14:2179. PubMed
  29. Fathi M, et al. 2023. iScience. 26:106482. PubMed
  30. Xiao C, et al. 2023. Nat Aging. 3:418. PubMed
  31. Lv X, et al. 2023. Acta Pharm Sin B. 13:1631. PubMed
  32. Li X, et al. 2023. Nat Commun. 14:2929. PubMed
  33. Tundidor I, et al. 2023. Nat Commun. 14:3130. PubMed
  34. Chen K, et al. 2023. Gut Pathog. 15:28. PubMed
  35. Golubovskaya V, et al. 2023. Cancers (Basel). 15:. PubMed
  36. Martínez-Blanco Á, et al. 2021. Front Immunol. 12:713697. PubMed
  37. Feng, D., Guo, J., et al. 2025. Microbiol Spectr. 13(10),e0136225. PubMed
  38. Lv X, et al. 2022. Acta Pharm Sin B. 12:735. PubMed
  39. Muliaditan T, et al. 2021. Cell Rep Med. 2:100457. PubMed
  40. Tian L, et al. 2021. Int J Mol Sci. 22: . PubMed
  41. Datta S, et al. 2014. J Leukoc Biol. 95:853. PubMed
  42. Delás MJ, et al. 2019. Cell Rep. 27:719. PubMed
  43. Viborg N, et al. 2019. Oncoimmunology. 8:e1663107. PubMed
  44. Yamakawa N, et al. 2012. Int Immunol. 25:45. PubMed
  45. Grevers L, et al. 2013. Ann Rheum Dis. 72:278. PubMed
  46. Gatineau J, et al. 2022. Front Immunol. 13:982839. PubMed
  47. Trendel N, et al. 2021. Sci Signal. 14:eaay9363. PubMed
  48. Larsen SB, et al. 2021. Cell Stem Cell. 28:1758. PubMed
  49. Ruiz–Camp J, et al. 2019. EMBO Mol Med. 11:3. PubMed
  50. Nie X, et al. 2017. Cellular & Molecular Immunology. 10.1038/cmi.2017.17. PubMed
  51. Hernandez-Franco JF, et al. 2022. Front Immunol. 13:990900. PubMed
  52. Liang Q, et al. 2022. iScience. 25:104043. PubMed
  53. Xiao C, et al. 2022. iScience. 25:103934. PubMed
  54. Imbrechts M, et al. 2022. iScience. 25:104705. PubMed
  55. Biswas S, et al. 2021. Nature. 591:464. PubMed
  56. Wellner A, et al. 2021. Nat Chem Biol. 17:1057. PubMed
  57. Gniffke EP, et al. 2020. medRxiv. . PubMed
  58. Kim Y, et al. 2015. PLoS One. 10:120294. PubMed
  59. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  60. Ashbaugh J, et al. 2013. J Immunol. 190:4525. PubMed
  61. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  62. Hu Y, et al. 2022. Nat Commun. 13:5313. PubMed
  63. Yamamoto K, et al. 2021. Cell Reports. 36(8):109576. PubMed
  64. Im S, et al. 2016. Nature. 537:417-421. PubMed
  65. Nishimoto K, et al. 2008. J Immunol. 181:4010. PubMed
  66. Cao Y, et al. 2022. Nature. :. PubMed
  67. He X, et al. 2021. Emerg Microbes Infect. 10:1555. PubMed
  68. Tsukamoto H, et al. 2013. Biochem Biophys Res Commun. 440:31. PubMed
  69. Phiwpan K, et al. 2015. PLoS One. 10:128198. PubMed
  70. Schanda N, et al. 2021. Cells. 10:. PubMed
  71. Weiß S, et al. 2020. J Infect Dis. 222:1629. PubMed
  72. Lucas A, et al. 2015. PLoS One. 10:117160. PubMed
  73. Niki T, et al. 2009. J Biol Chem. 284:32344. PubMed
  74. Ping Y, et al. 2020. Front Cell Dev Biol. 0.890972222. PubMed
  75. Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
  76. Pfenninger P, et al. 2022. Front Immunol. 13:777113. PubMed
  77. Kristensen NP, et al. 2022. J Clin Invest. 132:. PubMed
  78. Qiu C, et al. 2022. Front Immunol. 12:764949. PubMed
  79. Cao Y, et al. 2022. Nature. 602:657. PubMed
  80. Rogers BM, et al. 2021. J Exp Med. 218:. PubMed
  81. Köchl R, et al. 2020. Elife. 9:00. PubMed
  82. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  83. Hansen UK, et al. 2020. Front Immunol. 11:373. PubMed
  84. Reading J, et al. 2013. J Immunol. 190:4542. PubMed
  85. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  86. Mei H, et al. 2021. J Hematol Oncol. 14:161. PubMed
  87. Repáraz D, et al. 2022. J Immunother Cancer. 10:. PubMed
  88. Weiß S, et al. 2020. medRxiv. . PubMed
  89. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
  90. Hebbar N, et al. 2022. Nat Commun. 13:587. PubMed
  91. Tschismarov R, et al. 2021. JCI Insight. 6:. PubMed
  92. Richardson LS, et al. 2020. Lab Chip. 3.948611111. PubMed
  93. McWilliam H, et al. 2016. Nat Immunol. 17: 531-537. PubMed
  94. Zhang S, et al. 2016. Sci Transl Med. 8: 341ra77. PubMed
  95. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
  96. Van Gool F, et al. 2019. Immunity. 50:362. PubMed
  97. Mainini F, et al. 2015. PLoS One. 10: 0145403. PubMed
  98. Woo S, et al. 2013. J Leukoc Biol. 93:363. PubMed
  99. Baccala R, et al. 2012. J Immunol. 189:5976. PubMed
  100. Delacher M, et al. 2020. Immunity. 52:295. PubMed
  101. Tsukamoto H, et al. 2017. FEBS Lett. 10.1002/1873-3468.12768. PubMed
  102. Parente-Pereira AC, et al. 2022. STAR Protoc. 3:101319. PubMed
  103. Baltierra-Uribe SL, et al. 2021. Eur J Immunol. 51:2641. PubMed
  104. Schoutrop E, et al. 2022. Oncoimmunology. 11:2093426. PubMed
  105. Jiang Y, et al. 2021. Cell Death Differ. 28:3009. PubMed
  106. Günaydın G, et al. 2014. Vaccine. 32:470. PubMed
  107. Matt P, et al. 2015. PLoS One. 10: 0137474. PubMed
  108. Davis Z, et al. 2016. PLoS Pathog. 12: 1005421. PubMed
  109. Carestia A, et al. 2019. Cell Rep. 28:896. PubMed
  110. Scatizzi J, et al. 2012. J Immunol. 188:3307. PubMed
  111. Tian B, et al. 2017. Front Immunol. 10.3389/fimmu.2017.00956. PubMed
  112. Schoofs T et al. 2019. Immunity. 50(6):1513-1529 . PubMed
  113. Guo C, et al. 2021. Cell Rep Med. 2:100448. PubMed
  114. Chen YL, et al. 2021. J Biol Chem. :101420. PubMed
  115. Zhong MC, et al. 2021. J Exp Med. 218:. PubMed
  116. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  117. Roewe J, et al. 2020. Nat Commun. 3.260416667. PubMed
  118. Morikawa M, et al. 2016. PLoS One. 11:e0163607. PubMed
  119. Leung EYL, et al. 2020. Mol Ther Oncolytics. 16:289. PubMed
  120. Nowak W, et al. 2020. EBioMedicine. 50:290-305.. PubMed
  121. Matsuda T, et al. 2022. iScience. 25:105324. PubMed
  122. Kim SP, et al. 2022. Cancer Immunol Res. :OF1. PubMed
  123. Cheloha RW, et al. 2021. RSC chem biol. 2:1692. PubMed
  124. Okamoto Y, et al. 2021. J Cell Sci. 134:. PubMed
  125. Gniffke EP, et al. 2020. J Infect Dis. 222:1965. PubMed
  126. Wang W, et al. 2014. Proc Natl Acad Sci U S A. 111:14466. PubMed
  127. Miyauchi K, et al. 2016. Nat Immunol. 17:1447-1458. PubMed
  128. Lu X, et al. 2019. Cell Rep. 28:472. PubMed
  129. Andersen TK, et al. 2019. NPJ Vaccines. 4:9. PubMed
  130. Hoffmann J, et al. 2021. Nat Commun. 12:3964. PubMed
  131. He X, et al. 2014. J Immunol. 193:1314. PubMed
  132. Kanno A, et al. 2013. Int Immunol. 25:413. PubMed
  133. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  134. Dan JM, et al. 2021. Science. :371. PubMed
  135. Murakami Y, et al. 2014. J Immunol. 193:5208. PubMed
  136. Mchedlidze T, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.20. PubMed
  137. Walker MR, et al. 2022. Sci Adv. 8:eabj9513. PubMed
  138. Yang Zhou J, et al. 2022. Front Immunol. 13:898473. PubMed
  139. Deng J, et al. 2021. J Leukoc Biol. 110:1171. PubMed
  140. DanDan Huang, Lang Bao 2016. J Microbiol Immunol Infect. 49:859-865. PubMed
  141. Chappaz S, et al. 2010. J Immunol. 185:3514. PubMed
  142. Altman JB, et al. 2018. Health Sci Rep. 1:e74. PubMed
  143. Hirunwidchayarat W, et al. 2017. Biochem Biophys Res Commun. 10.1016/j.bbrc.2017.07.012. PubMed
  144. Wang EY, et al. 2022. Cell Rep Methods. 2:. PubMed
  145. Kurashima Y, et al. 2021. Nat Commun. 12:1067. PubMed
  146. Wells DK, et al. 2020. Cell. 183:818. PubMed
  147. Schürch CM, et al. 2020. Cell. 182:1341. PubMed
  148. Lyngaa R, et al. 2014. Clin Cancer Res. 20:1768. PubMed
  149. Tripathi S, et al. 2016. Proc Natl Acad Sci U S A. 113: 1555 - 1564. PubMed
  150. Ando Y, Oku T, Tsuji T 2016. PLoS One. 11: 0162208. PubMed
  151. Zheng Q, et al. 2017. Mol Oncol. 10.1002/1878-0261.12056. PubMed
  152. Pedersen NW, et al. 2019. Nat Commun. 10:837. PubMed
  153. Yang C, et al. 2019. Nat Commun. 10:3931. PubMed
  154. Xiao C, et al. 2021. STAR Protoc. 2:100789. PubMed
  155. Rodrigues KA, et al. 2021. Sci Adv. 7:eabj6538. PubMed
  156. Szeto C, et al. 2022. Nat Commun. 13:4951. PubMed
  157. Yoshikawa S, et al. 2016. Sci Rep. 6:18738. PubMed
  158. Shibui A, et al. 2011. Exp Parasitol. 129:318. PubMed
  159. Lautz JD, et al. 2019. Sci Rep. 9:10890. PubMed
  160. Kenney M, et al. 2017. Journal of Immunological Methods. 10.1016/j.jim.2017.07.001. PubMed
  161. Holm JS, et al. 2022. Nat Commun. 13:1935. PubMed
  162. Wirasinha RC, et al. 2021. J Exp Med. 218: . PubMed
  163. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 6    Revision Date: 06.17.2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account